Bitcoin Updates: Collapse of Crypto Market Makers Sparks 8-Day Wave of Fear Amid Deepening Liquidity Crunch
- Crypto Fear & Greed Index hit 19 for 8 days, signaling extreme panic amid $420M ETF outflows and liquidity crises. - Market makers collapsed due to stablecoin mispricing, wiping 2M accounts and amplifying volatility since October. - Malaysia cracks down on $1B-loss crypto mining , while Bitfury shifts $1B to tech amid plunging mining profits. - Trump family lost $1.3B in crypto assets, including Bitcoin mining and memecoins, despite claiming volatility as opportunity. - Experts predict 6-8 week stabiliza
The Crypto Fear & Greed Index, widely regarded as a crucial indicator of investor mood,
This extended period of fear is the result of several converging challenges. Since October, U.S. spot crypto ETFs have seen net outflows exceeding $420.8 million, with
Regulatory and operational challenges are making the situation worse. In Malaysia, authorities are cracking down on illegal crypto mining after estimating that such activities have cost the national grid $1 billion.
Major losses among prominent players further highlight the market's instability. The Trump family's crypto-related businesses have seen their value drop by over $1.3 billion since September, with their Bitcoin holdings, memecoins, and mining interests all suffering. Donald Trump Jr. and Eric Trump's mining company,
Past trends indicate that once liquidity returns, the market could recover quickly. The current setup, with spot ETFs and institutional infrastructure, is much more robust than during the 2022 collapse. Analysts
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Solana News Update: Sunrise Seeks to Resolve Solana's Liquidity Splintering through Immediate Listings
- Wormhole Labs launches Sunrise, a Solana-native listing platform enabling instant liquidity for new tokens like MON, addressing DeFi fragmentation. - The platform uses NTT framework to natively onboard cross-chain assets, retaining liquidity within Solana and integrating with DEXs like Orb and Jupiter. - MON's day-one trading demonstrates Sunrise's potential to solidify Solana as a hub for tokenized assets, with TVL rising 32.7% to $11.5B in Q3 2025. - Analysts highlight Sunrise's role in standardizing h

India’s Cryptocurrency Conundrum: Can Updated VDA Regulations Safeguard Progress or Hinder Expansion?
- India's VDA regulatory review aims to align crypto rules with global standards, addressing consumer protection gaps and market integrity risks. - Current fragmented regulations, including 30% profit tax and weak custody laws, have driven users to offshore platforms, stifling local innovation. - Proposed reforms include risk-based token classification, licensing for exchanges, and RWA frameworks to balance innovation with systemic risk mitigation. - A balanced approach could attract investment and strengt

Bitcoin Updates Today: Bearish Pressure Mounts, Yet Optimistic Bulls Anticipate Future Expansion
- Bitcoin's bearish technical indicators reinforce downward pressure despite short-term recovery attempts. - Ethereum and altcoins mirror Bitcoin's weakness, with $2B in crypto liquidations intensifying selling pressure. - Long-term fundamentals project $17.14B crypto market growth by 2033 driven by institutional adoption and regulatory clarity. - Thailand's Bitkub plans $200M Hong Kong IPO amid local market struggles, highlighting regional listing strategy shifts. - Persistent bearish momentum remains, wi

Biomarkers Shine, Results Disappoint: Novo's Attempt at Alzheimer's Falls Short
- Novo Nordisk's Alzheimer's trials for semaglutide failed to meet primary endpoints, causing a 9% premarket stock drop to a multi-year low. - The $3.8B trial showed no disease progression slowing despite biomarker improvements, with UBS estimating only 10% success probability beforehand. - Market ripple effects included Eli Lilly's 0.5% decline and Biogen's 2.7% rise, highlighting GLP-1 drug competition in neurodegenerative therapies. - This setback compounds Novo's challenges: 50% YTD stock decline, obes
